High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid
Journal of Antimicrobial Chemotherapy · 01.08.2025 · 80 (8) · 2080-2091
DOI: 10.1093/jac/dkaf169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 09.07.2025. Verfasst von Hitoshi Kawasuji und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan. Hauptthemen laut MEDLINE: Linezolid, Saliva, Drug Monitoring, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Japanese Society of Chemotherapy Foundation, Japan Research Foundation for Clinical Pharmacology, Japan Society for the Promotion of Science KAKENHI.
Abstract (Originalsprache)
Background
Salivary therapeutic drug monitoring (TDM) offers the potential to reduce the risks, burden, time and costs of blood-based TDM, but its feasibility for use with oxazolidinone antibiotics and the influence of food intake remain unknown.
Methods
We conducted a healthy subject study with 12 healthy participants. Linezolid and tedizolid were intravenously administered to 6 participants each. Saliva and peripheral venous blood samples were taken simultaneously at 12 time points and their correlations were evaluated, including a determination of whether these correlations were sustained after food intake. A monocentric prospective exploratory study was then conducted in 10 patients. Total and unbound serum and saliva concentrations were measured using high-performance liquid chromatography.
Results
In healthy participants administered linezolid, individual concentration–time curves for saliva were similar to those for serum (total and unbound), but the saliva and serum concentration–time curves differed for tedizolid. Saliva concentrations in each case and area under the concentration–time curve from 0 to 10 h (AUC0–10) in saliva were correlated with those in total or unbound serum for linezolid, but not for tedizolid. Food intake did not influence the correlations in linezolid. In the exploratory study in 10 patients administered linezolid, saliva concentrations correlated with total or unbound serum concentrations in both non-haemodialysis (n = 7) and haemodialysis (n = 3) patients, irrespective of dosages, administration routes, timing or eating and drinking restrictions.
Conclusions
Salivary TDM is a promising alternative to conventional serum sampling for linezolid but is less feasible for tedizolid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
- Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University, Funabashi, Chiba, Japan.
ORCID-Profile: Hitoshi Kawasuji, Kentaro Nagaoka, Yoshihiro Yamamoto
Förderung
- Japanese Society of Chemotherapy Foundation
- Japan Research Foundation for Clinical Pharmacology
- Japan Society for the Promotion of Science KAKENHI
Zitieren
APA
Kawasuji, H., Tsuji, Y., Miyaki, K., Aoyama, T., Kurosaki, F., Ezaki, M., Koshiyama, Y., Takegoshi, Y., Kaneda, M., Murai, Y., Kimoto, K., Nagaoka, K., & Yamamoto, Y. (2025). High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid. Journal of Antimicrobial Chemotherapy, 80(8), 2080-2091. https://doi.org/10.1093/jac/dkaf169
Vancouver
Kawasuji H, Tsuji Y, Miyaki K, Aoyama T, Kurosaki F, Ezaki M, et al. High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid. Journal of Antimicrobial Chemotherapy. 2025;80(8):2080-2091. doi:10.1093/jac/dkaf169
BibTeX
@article{Kawasuji2025,
author = {Kawasuji, Hitoshi and Tsuji, Yasuhiro and Miyaki, Keiko and Aoyama, Takahiko and Kurosaki, Fumihiro and Ezaki, Masayoshi and Koshiyama, Yuki and Takegoshi, Yusuke and Kaneda, Makito and Murai, Yushi and Kimoto, Kou and Nagaoka, Kentaro and Yamamoto, Yoshihiro},
title = {High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {8},
pages = {2080--2091},
doi = {10.1093/jac/dkaf169}
}
EUVIMED